Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661167 | 0.86 | PTGDR2 (0.41) | P2RX7CCR2KDM4EMEN1KMT2A | |
| SCHEMBL3741636 | 0.81 | ALKBH1 (0.35) | P2RX7MEN1KMT2A | |
| SCHEMBL2661784 | 0.80 | AR (0.41) | P2RX7CCR2 | |
| SCHEMBL2661992 | 0.80 | PTGER4 (0.39) | P2RX7CCR2PPARG | |
| SCHEMBL2661123 | 0.79 | ALDH1A1 (0.46) | KDM4EATMKMT2AALDH1A1GAA | |
| SCHEMBL3746593 | 0.78 | MAPT (0.43) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2655497 | 0.78 | PTGDR2 (0.39) | CCR2KDM4EALDH1A1 | |
| SCHEMBL3743679 | 0.77 | L3MBTL1 (0.44) | CCR2KDM4EKMT2AALDH1A1 | |
| SCHEMBL2661140 | 0.77 | CYP2D6 (0.46) | KDM4ETDP1KMT2AALOX5APALDH1A1 | |
| SCHEMBL3748509 | 0.77 | ABCB11 (0.50) | P2RX7CCR2PPARGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | disclosed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, PCK1, GCKR | CMA1 1750/4885EPHX2 4042/4885P2RX7 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.